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Background: Cardiac troponin-I (cTNI) is highly specific biomarker to prove myocardial damage, e.g. in acute
coronary syndrome (ACS). However, it occurs in other conditions as well. We therefore analysed cTNI increase in
patients after generalized convulsive seizure.
Methods: Consecutive patients admitted with acute generalized convulsive seizure were included in case of cTNI
measurement on admission. Among 898 selected cases, 53 patients were referred secondary to our department; in
845 cases cTNI measurements on admission were available. In case of multiple admissions (81 cases), only the first
admission entered our analysis. In 17 patients elevated cTNI was determined due to ACS; in one patient a
myocarditis was found. 5 patients suffered of relevant renal insufficiency. Finally 741 patients were included in the
analysis. A cTNI cut-off level of≥ 0.1 ng/ml was considered. Factors associated with a cTNI increase were analysed
subsequently.
Results: The mean age of the study population (n = 741) was 47.8 years (SD ± 18.6), 40.9% were female. In 50
patients (6.7%) a cTNI elevation of unknown origin was found; no obvious cardiac involvement could be detected
in these patients who all remained asymptomatic. A vascular risk profile (including at least hypertension,
hypercholesterolemia or diabetes) (OR = 3.62; CI: 1.59 to 8.21; p= 0.001) and elevated creatine kinase on admission
(OR = 2.36; CI: 1.26 to 4.39; p= 0.002) were independent factors associated with cTNI release.
Conclusion: cTNI release occurs in patients with generalized convulsive seizure with predominance in patients with
vascular risk profile.
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Cardio-specific biomarkers have been considered the
most reliable factors for the diagnosis of myocardial in-
farction [1,2]. Especially cardiac troponin-I (cTNI) is
highly specific for myocardial muscular tissue damage
and is never expressed after skeletal musculature injury
[3]. Unexplained cTNI increase occurring in different
conditions, e.g. septic conditions, critical illness, endocrine* Correspondence: Christian.Tanislav@neuro.med.uni-giessen.de
†Equal contributors
1Departments of Neurology, Justus Liebig University Giessen, Giessen,
Germany
7Department of Neurology, Justus Liebig University, Giessen, Klinikstrasse 33,
35385 Giessen, Germany
Full list of author information is available at the end of the article
© 2012 Sieweke et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the oror neurologic disorders led to the assumption of other
mechanisms of cTNI release than commonly determined
by myocardial ischemia in acute coronary syndrome
(ACS) [4-11].
Approaching the pathophysiology of non-myocardial
ischemic cTNI release, several investigations addressed
disorders with involvement of the central nervous sys-
tem in particular stroke and subarachnoidal haemor-
rhage [12-15]. Evidence on troponin elevation after
seizures is based on limited data [16-20]. A better under-
standing on cTNI release in other conditions than an
ACS is highly relevant with potential impact for the
diagnostic and therapeutic management. Therefore in
the present study we aimed to investigate the frequency
of cTNI release after generalized convulsive seizure.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Patients and data acquisition
Consecutive patients (n = 898) hospitalized in terms of
an acute generalized convulsive seizure were identified
from records relevant for hospital payment. The diagno-
sis of a generalized convulsive seizure was proven by
reviewing the patients’ case files. The diagnosis of the
generalized convulsive seizure was settled and documen-
ted in the payment records and patients’ case files
according to the physician judgment. As the cTNI meas-
urement on admission is implemented in our routine la-
boratory testing in a high percentage of patients, cTNI
assessments were performed (n = 845). 53 patients were
secondary referred to our department, thus cTNI mea-
surements on initial admission were not available. In
case of multiple admissions of an individual patient the
first admission was considered; for these reasons 81
cases were excluded. In 17 patients an elevated cTNI
was determined by an ACS; the diagnosis was estab-
lished based on subsequent work-up. In 5 patients a pro-
gressed renal insufficiency (serum creatinine> 3.0 mg/dl)
was evident. One patient was diagnosed with myocardi-
tis. Other conditions known for causing a cTNI release
including sepsis or rhabdomyolysis, concomitant pul-
monary embolism, acute strokes or cerebral haemor-
rhage were not evident [4-10]. Finally, 741 patients with
cTNI assessment on admission were included in the
analysis (Figure 1).
The following parameters were systematically recorded:
age, gender, known epilepsy, symptomatic epilepsy with
type of lesion and localization, intake of anticonvul-
sants prior to admission, regular alcohol consumption
prior to admission, previous myocardial infarction,
known coronary heart disease (CAD) as diagnosed by
coronary angiography, intake of beta-blockers, hyper-
tension (if known and treated), hypercholesterolemia (if
known and treated) and diabetes (if known and trea-
ted). If one of the conditions consisting of hypertension,Figure 1 Patients selection for eligibility (admission with
generalized seizure and cardiac troponin I (cTNI)
measurement). Legend: * serum creatinine> 3.0 mg/dl.hypercholesterolemia or diabetes were present, the pa-
tient was rated as having a vascular risk profile. The
factor smoking could not be assessed due to inconsist-
ent documentation. In patients with cTNI elevation the
subsequent cardiac work-up was documented (coronary
angiography if performed, echocardiography, ECG,
24 h-ECG, routine lab).
The study protocol was reviewed and approved by the
local ethical committee of the Justus Liebig University,
Giessen, Germany.
Blood samples
For measurements of cTNI levels, the ADVIA CentaurW
TnI-Ultra™ immunoassay (Bayer HealthCare, Tarrytown
USA) was used. According to the local standards, a cTNI
cut-off level of ≥ 0.1 ng/ml was considered a significant
elevation; values of 0.1 ng/ml on admission were rated
as increased when the second sample confirmed an ele-
vation of ≥ 0.1 ng/ml.
The creatine kinase (CK) values were assessed using
the CKNAC-kit for ADVIA Chemistry Systems and cre-
atinine (Cr) values were measured by creatinin_2-kit for
ADVIA Chemistry Systems (Bayer HealthCare, Tarry-
town USA). A CK cut-off level of> 140U/l in females
and> 174 U/l in males was considered as elevation. For
Cr values cut-off levels of> 1.2 mg/dl in females
and> 1.3 mg/dl in males were rated as significantly
increased. Further, in all patients an estimated glomeru-
lar filtration rate (eGFR) was calculated according to the
simplified MDRD equation: eGFR (ml/min/1,73 m2 body
surface) = 186 x (serum creatinine)-1.154 x (age)-0.203 x 0.742
(if female) x 1.212 (if black) [21]. All routine laboratory
tests were performed using certified methods.
Statistical Evaluation
Normal distribution was verified by Kolmogorov-
Smirnov’s one-sample test. Nonparametric data was ana-
lysed employing a Mann–Whitney U-test. For compar-
ing relative frequencies, a Fisher’s exact test was used.
Data significant on univariate analysis were entered into
a logistic regression analysis based on a forward likeli-
hood procedure. For the statistical analysis the SPSS
Software (Statistical Package for Social Sciences) release
15.0 (SPSS Inc., Chicago, IL, USA) was used.
Results
Among 741 patients who were included in the final ana-
lysis, 40.9% were female; the mean age was 47.8 years
(SD ±17.5). In 50 patients (6.7%) a cTNI elevation was
noted (Table 1). Symptoms related to an ACS were not
present in any of these patients. Based on the recom-
mendation of the cardiologists in 19 of these patients a
coronary angiography was undertaken ruling out any
findings suggestive of an ACS or relevant CAD. Serial
Table 1 Gender specific comparison of CK and Cr values
cTNI elevation cTNI negative P
Female (n = 303) n = 19 n= 284
CK values (U/l) on admission; median (range) 142 (39 – 7705) 137 (12 – 1792) 0.07
Elevated CK values on admission 10 (52.6%) 105 (37.0%) 0.22
Further CK increase after admission 9 (47.4%) 69 (24.3%) 0.05
Cr values (mg/dl) on admission, median (range) 1.0 (0.7 – 1.6) 1.0 (0.5 – 2.6) 0.35
Elevated Cr values on admission 5 (26.3%) 29 (10.2%) 0.05
Male (n = 438) n = 31 n= 407
CK values (U/l) on admission; median (range) 167 (29 – 13547) 145 (21 – 42143) 0.46
Elevated CK values on admission 17 (54.8%) 171 (42.0%) 0.18
Further CK increase after admission 15 (48.4%) 94 (23.1%) 0.004
Cr values (mg/dl) on admission, median (range) 1.2 (0.1 – 1.9) 1.1 (0.5 – 2.8) 0.36
Elevated Cr values on admission 11 (35.5%) 40 (9.8%) <0.001
cTNI refers to serum cardiac troponin I.
CK refers to serum creatine kinase.
Cr refers to serum creatinine.
CK cut-off level> 140U/l in females and> 174 U/l in males.
Cr cut-off level> 1.2 mg/dl in females and> 1.3 mg/dl in males.
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patients remained unremarkable. In all patients with
cTNI release of unknown origin, a systematic retrospect-
ive review of ECG and 24 h-ECG examinations was
undertaken, excluding any findings suggestive of acute
myocardial ischemia. Echocardiography in all patients
did not reveal any results indicating myocardial wall
hypokinesia or dyskinesia; also an apical ballooning, the
typical echocardiographic finding in a stress induced car-
diomyopathy, also known as Takotsubo cardiomyopathy,
could not be detected [22,23]. In 46 patients, maximum
cTNI values of ≥ 0.2 ng/ml were found; in 4 patients a
value of 0.1 ng/ml was not exceeded. In 40 patients the
cTNI level decreased the day after admission, whereas in
10 patients a further increase could be observed (a cTNI
value of 1.6 ng/ml was not exceeded).
In 303 patients (40.9%), an elevated CK on admission
was evident; a further increase of CK after the initial
evaluation was observed in 187 (25.2%) participants. Ele-
vated Cr values on admission were found in 85 patients
(11.5%). There was no difference in the calculated eGFR
values in the group with cTNI elevation versus without
(Table 2). As for CK and Cr normal ranges are sex
dependent, absolute values for males and females are
separately reported in Table 1.
cTNI release was associated with age, elevated CK
and Cr on admission, intake of beta-blockers, known
CAD, vascular risk profile, known epilepsy and intake
of anticonvulsants (Table 2). Entered into a logistical
regression analysis, a vascular risk profile (p = 0.001;
OR: 3.62; CI: 1.59-8.21) and elevated CK values on ad-
mission (p = 0.002; OR: 2.36; CI: 1.26-4.39) were inde-
pendently associated with cTNI release. In patients witha symptomatic epilepsy a cTNI release did not correlate
with the location of the corresponding lesion (left sided
lesions: 13/23 vs. 132/226; right sided lesions: 15/23 vs.
141/226, p = 0.99) or bilateral lesions (5/23 vs. 47/226,
p = 0.99).
Discussion
The primary finding of the present study is a cTNI ele-
vation of unknown origin in a remarkable percentage of
patients (6.7%) presenting with acute generalized convul-
sive seizures. A vascular risk profile - defined as the
presence of at least one of the risk factors hypertension,
diabetes or hypercholesterolemia - was identified as the
main independent associated factor.
The pathophysiology behind the cTNI release of un-
known origin in patients with different disorders is con-
troversial. Some authors support the hypothesis of a
“reversible ischemia model” due to a temporarily reduced
coronary blood flow [7,13,20,24]. Others groups propose
an autonomic involvement resulting from alterations of
the central nervous system, predominantly causing a
sympathetic overactivity [12,14]. Taking into account the
short interval of global ischemia during a generalized
convulsive seizure together with a pre-existing cardiac
microvascular disturbance as a result of vascular burden,
our results support the mechanism of a temporary car-
diac ischemia. This mechanism explains potentially the
regular findings in the subsequent cardiac work-up and
the lack of cardiac clinical signs.
The presence of vascular risk factors consisting of
hypertension and/or hypercholesterolemia and/or dia-
betes was the main factor associated with a cTNI eleva-
tion. Reviewing the literature the vascular burden is
Table 2 Relationship between selected parameters and cTNI elevation in patients with epileptic seizure
Total cohort (n = 741) cTNI elevation(n =50) cTNI negative(n= 691) P* P†
Age (years); median (range) 47.8 (17.5 –89.9) 61.9 (21.6 – 88.1) 46.8 (17.5 – 89.9) <0.001 0.07
Gender 0.77
Female 303 (40.9%) 19 (38%) 284 (41.1%)
Male 438 (59.1%) 31 (62%) 407 (58.9%)
CK elevated on admission 303 (40.9%) 27(54%) 276 (39.9%) <0.001 0.002
Further subsequent CK
increase after admission
187 (25.2%) 24 (48%) 163 (23.6%) <0.001
Cr elevated on admission 85 (11.5%) 16 (32%) 69 (10%) 0.05 0.14
eGFR (ml/min/1,73 m2 body surface),
median (range)
76.9 (43.8 – 162.8) 76.1 (45.9 – 162.8) 76.9 (43.8 – 159.3) 0.40
Hypertension 155 (20.9%) 16 (32%) 139 (20.1%) 0.07
Hypercholesterolemia 117 (15.8%) 12 (24%) 105 (15.2%) 0.11
Diabetes 75 (10.1%) 9 (12%) 66 (9.6%) 0.08
Intake of Beta-blocker 92(12.4%) 15(30%) 77 (11.1%) <0.001 0.63
Known CAD 96 (13%) 18 (36%) 78 (11.3%) <0.001 0.56
Vascular risk profile 193 (33.9%) 32(64%) 161(23.3%) <0.001 0.001
Regular alcohol consumption 222 (30%) 17 (34%) 205 (29.7%) 0.52
Known epilepsy 251 (33.9%) 25 (50%) 226 (32.7%) 0.02 0.18
Symptomatic epilepsy 249 (33.6%) 23 (46%) 226 (32.7%) 0.06 0.52
Intake anticonvulsants 231 (31.2%) 23 (46%) 208 (30.1%) 0.02 0.34
*P value calculated in the univariate analysis.
†P value calculated in the logistical regression.
CK refers to serum creatine kinase.
Cr refers to serum creatinine.
CK cut-off level> 140U/l in females and> 174 U/l in males.
Cr cut-off level> 1.2 mg/dl in females and> 1.3 mg/dl in males.
eGFR refers to estimated glomerular filtration rate.
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elevation without obvious cardiac involvement. The dis-
tribution of risk factors in these studies complies well
with our findings. In stroke cohorts, a vascular burden
per se could be assumed [25,26]. In studies investigating
a cTNI elevation in critical illness in a high percentage
of patients vascular risk factors were evident: diabetes
33%, hypertension 53% and hypercholesterolemia 37%
[24]. Even analyses within heterogeneous cohorts dem-
onstrated a considerable vascular burden [7]. Our find-
ings might also support the hypothesis of vascular risk
profile being a prerequisite for cTNI elevation in other
conditions then ACS. In this context there is no pre-
dominating risk factor; the hypertension seems to pos-
sess the strongest association with increased cTNI levels.
There is evidence supporting the hypothesis that CK
levels directly correlate with seizure duration [27,28].
Increased CK levels could therefore be interpreted as a
result of extended phases of global ischemia. In our
study, patients with cTNI release presented more fre-
quently with elevated CK values. This is in line with
findings depicted by Eskandarian and co-workers, who
demonstrated on average higher troponin levels after
complicated seizers as indicated by different heartcirculatory parameters [16]. In this context, supposing
larger intervals of general ischemia in case of “compli-
cated” seizures, this might also support the mechanism
of a temporary ischemia behind cTNI elevation.
The approach to localize a specific brain region pos-
sibly generating cTNI release is controversial [29,30].
The heterogeneity of lesions in our study does not allow
a more precise analysis. However, specific hemisphere
vulnerability for inducing a cTNI elevation was not
evident.
The implementation of cTNI measurement in routine
laboratory testing on admission enabled the acquisition
of a large series of patients with cTNI assessment after
an acute generalized convulsive seizure. Missing patients
are unlikely because the data base used is also the basis
for hospital payment. Similar to previous investigations,
a detailed evaluation of the renal function is not avail-
able in our study. As some investigators identified a
reduced glomerular filtration rate as potentially respon-
sible for increased troponin levels, in this context detailed
evaluation of the renal function appears mandatory. In
our study increased creatinine levels, allowing certain es-
timation of the renal function were not associated with a
cTNI increase [31]. Concerning the renal function, there
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filtration rate values between patients with cTNI eleva-
tion versus without. This suggests the observed cTNI ele-
vation did not result from an impaired renal function.Methodological limitations of the study
Due to its retrospective design, the main limitation of
the present study is the inability to reliably estimate the
duration of the seizure in an individual patient. As gen-
eral ischemia seems to be defining factor for the devel-
opment of seizure-related cTNI elevation, the duration
of the event is important [16]. Hence, this aspect needs
verification in further examinations especially as elevated
CK-levels indicating extended seizures are associated
with cTNI elevation [27,28].
Blood samples for cTNI measurements were routinely
collected on admission. However, the time between the
event and the admission was not regularly documented
in the patients’ case records. Therefore, the retrospective
data acquisition does not allow a precise determination
of these time intervals. As the period from seizure to ad-
mission might influence the cTNI-level, this aspect
needs to be considered as potential bias interpreting the
current results.
A further limitation of the present study is the hetero-
geneous cardiac work-up in patients with cTNI release.
However, in all patients an ACS as a cause of cTNI ele-
vation was sufficiently ruled out. The systematic retro-
spective review of relevant cardiological examinations
(ECG, 24 h-ECG and echocardiography) did not reveal
findings suggestive of acute myocardial ischemia or even
a Takotsubo cardiomyopathy.
Patients with generalized seizures were identified from
a database collecting relevant data for hospital payment.
The diagnosis is therefore based on the treating physi-
cians’ judgment. To minimize bias caused by transcrip-
tion errors, all patients’ files were intensively reviewed in
order to prove the qualifying event.Conclusion
A cTNI release occurs after generalized convulsive seiz-
urewithpredominance inpatientswithvascularrisk factors.
Elevated CKvalues, as a potential marker for extended sei-
zures, are associated with this phenomenon. Since cTNI
is highly relevant for the diagnosis of myocardial tissue
damage, further approaches investigating the mechan-
isms cTNI release are promptly required.Ethical approval
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